Form 4: Apyx Medical Corp CEO Charles D. Goodwin II Acquires 50,000 Stock Options

Charles D. Goodwin II, CEO of Apyx Medical Corp, reports the acquisition of 50,000 stock options on January 15, 2025.

Summary

• Charles D. Goodwin II, the CEO of Apyx Medical Corp, filed a Form 4 on January 17, 2025.
• The report details a transaction on January 15, 2025, where Goodwin acquired 50,000 stock options.
• These options have an exercise price of $1.42.
• The options vest ratably over a 36-month period and will be fully vested and exercisable on the third anniversary of the grant date, January 15, 2028.
• The expiration date for these options is January 15, 2035.
• Following the reported transaction, Goodwin directly owns 50,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself could be seen as mildly positive, reflecting confidence, but the document is purely informational.

Positives

• The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the medical device industry.
• Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially incentivize the CEO to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates